Background and Aims: Hemophagocytic syndrome (HPS) is a fatal complication of severe viral infections such as Epstein-Barr virus (EBV) and recently, SARS CoV, and H5N1 influenza. The pathogenesis of HPS is presumed to result from an enhanced proinflammatory cytokine secretion and systemic macrophage activation. Previously, we demonstrated that EBV LMP-1 can activate T-cells and upregulate tumor necrosis factor-alpha and interferon-gamma, mediated through the NFkB/ATF5/SAP/ERK signaling, to activate macrophages. Since peroxisome proliferators activated receptor (PPAR) agonists, regulators of cholesterol metabolism, have been shown to exhibit profound effects on the inhibition of proinflammatory cytokines and macrophage activation through NFkB and AP-1 signaling, we adopted a PPAR-g agonist, rosiglitazone, for the potential therapy of HPS using a rabbit model of Herpesvirus papio (HVP, an EBV homologue)-associated HPS. Materials and Results: In vitro, rosiglitazone was shown to inhibit macrophage activation and secretion of tumor necrosis factor-alpha (TNF-a) through inhibition of NFkB signaling in THP1 cell line. Different doses of rosiglitazone were then fed to rabbits after intravenous injection of 5×107 copies of HVP virus at different time courses (7 days and 20 days, respectively) of infection. As compared to the control group which succumbed consistently at around one month, the 4 mg rosiglitazone-treated group showed significant improvement of survival when fed at early stage (7 days) of infection (p < 0.01), while a higher dosage (8 mg) is needed to achieve therapeutic effect at advanced stage (20 days) of infection (p < 0.05). The viral load, TNFa cytokine levels, and laboratory parameters also showed significant improvement in the rosiglitazone-treated group. Conclusion: PPAR agonist, in addition to its therapeutic effect for metabolic syndrome, appears to represent a potential regimen of new concept for the control of HPS associated with severe virus infections. 
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OL-046 Efficacy of interferon plus ribavirin therapy in chronic hepatitis C Patients: A Nepali study K.C. Sudhamshu *. Liver Unit, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal Backgrounda and Aim: Before the availability of pegylated interferon, interferon therapy in chronic hepatitis C patients was almost a failure in Nepal. This study was carried out to determine the efficacy of peg-interferon (2a) plus ribavirin in Nepali patients. Method: Thirty-seven consecutive patients with anti HCV test report were enrolled in the study from April 2004 to December 2007. Chronic hepatitis was confirmed by raised aminotransferase and presence of HCV RNA by PCR. Peg-interferon was given in a dose of 180 mcg per week subcutaneously and dose was adjusted whenever required. Ribavirin was given in a dose of 800 1000 mg/day. Viral load was repeated after 4th dose, 12th dose, last dose, after 3 month and 6 month of treatment. Results: Thirty-five patients showed detectable HCV RNA by PCR. 30 patients were treated and 29 followed up as 1 patient was lost in follow up. The genotype was 1 in 5, 2 in 9, 3 in 15 patients. 14 patients were super responder (9 type 3 and 5 type 2), while 12 patients were free of virus after 12 weeks of treatment. End treatment response (ETR) was 100% and sustained viral response (SVR) was achieved in 96.5%. Neutropenia was the commonest side effect of interferon while side effects of ribavirin were not seen. Conclusions: Peg-interferon and ribavirin was well tolerated in Nepali patient. ETR was 100% and SVR was 96.5% in small cohort of patient. 12 weeks therapy may be considered in type 2 and 3 due to cost factor.
OL-047 Evaluation of anti-HCV samples deemed positive by chemiluminescent assay using recombinant immunoblot assay Y.L. Dou *, X.Z. Guo, A.P. Ni, W.J. Yan.
Department of Clinical Labs Union Medical College Hospital Chinese Academy of Medical Science, Beijing, 100730, China
Objective: To conduct confirmative study of anti-HCV positive samples deemed positive by the secondtier and third-tier hospitals in China using two fully automatic chemiluminescent assay instrument, i2000 (ARCHITECT iSystem) and ECI (the Ortho-Clinical Diagnostics Vitros ECI Anti-HCV with the use of the CHIRON RIBA (Recombinant Immunoblot Assay) HCV3.0strip immunoblot assay (SIA) method. For the purpose to evaluate the rationality positive boundary value of the s/co for screening the HCV-positive samples. A boundary value of s/co has been specified such that any sample screened positive with s/co ratio greater than the boundary value would be at least better than 95% truly positive and therefore need not to undergo confirmatory RIBA test. more accurate clinical diagnosis of HCV case. Methods: First, screen out Anti-HCV samples that signal-tocutoff (s/co) is 1 20 in the ARCHITECT-i2000 or the Vitros ECI is 1 35. Then, Chiron RIBA HCV3.0 SIA test was performed to confirm the Anti-HCV serological results from the two companies' instruments. Followed by checking the HCV RNA with real time PCR. Lastly, perform statistical ROC curve processing to determine the boundary value of S/CO for screening anti-HCVpositive samples. Results: Among the 203 samples, 33 (16%) were confirmed RIBA negative and HCV RNA negative; 93samples (46%) were found RIBA positive but in which only 30 (32.3%) samples were also HCV RNA positive, 77 samples (38%) were found RIBA indeterminate and HCV RNA negative. In terms of sensitivity, the ARCHITECT i2000 analyzer is 99% and the Vitros ECI was found to be 100%. In terms of specificity, the ARCHITECT i2000 was found to be 61%; The Vitros ECI to be 52%. In terms of anti-HCV position predictive value, the ARCHITECT i2000 analyzer was 100% on s/co > 6.06 while the Vitros ECI analyzer was 100% on s/co > 12.35. Conclusion: The criteria of Anti-HCV s/co > 1 is reasonable for screening test using fully automatic Chemiluminescent assay with assurance of sensitivity greater than 97%. The anti-HCV positive samples can be fairly confirmed if s/co > 6.05 is measured by the architect I2000 analyzer and s/co > 12.35 is measured by the Vitros ECI analyzer. When s/co is measured 1.0 6.5 by the ARCHITECT i2000 analyzer and 1.0 12.5 by the Vitros ECI analyzer, it is suggested to perform confirmatory RIBA HCV3.0 SIA test if affordable or perform HCV RNA test, but it may be more realistic to have periodic re-examination of anti-HCV samples.
OL-048 Identification of Helicobacter hepaticus and
Helicobacter species in liver samples from Egyptian patients with hepatitis C cirrhosis with or without hepatocellular carcinoma
